Is Ivermectin Good for Fatty Liver?

Is ivermectin good for fatty liver? It is a question increasingly asked online, but the short answer is no. Ivermectin is an antiparasitic medicine licensed in the UK for specific parasitic infections, and there is currently no robust clinical evidence supporting its use for fatty liver disease, known as MASLD. While some early laboratory and animal studies have explored possible mechanisms, no human trials have demonstrated benefit. This article explains what the current evidence shows, what UK guidelines recommend for fatty liver, and which treatments are actually supported by NICE and EASL guidance.

What is fatty liver disease and how is it treated on the NHS?

Fatty liver disease (MASLD) is treated on the NHS primarily through lifestyle changes, including 7 to 10 per cent weight loss, a balanced diet and regular exercise, alongside management of associated conditions such as type 2 diabetes and hypertension.

Fatty liver disease is a condition in which excess fat accumulates within liver cells, and it is broadly divided into two main types: metabolic dysfunction-associated steatotic liver disease (MASLD, previously called non-alcoholic fatty liver disease or NAFLD) and alcohol-related liver disease (ALD). MASLD is closely linked to obesity, type 2 diabetes, high blood pressure and raised cholesterol. NHS guidance and the British Liver Trust estimate that MASLD affects a substantial proportion of UK adults, with some sources suggesting around one in three people may have some degree of hepatic steatosis, though the exact figure varies by diagnostic threshold and population studied.^[4]

In its early stages, fatty liver disease often causes no symptoms and is discovered incidentally during blood tests or imaging. Without intervention, a proportion of people progress to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis or, in some cases, liver cancer. NICE guidance on NAFLD and MASLD assessment and management (including NG49 and subsequent updates) recommends that people with MASLD are assessed for cardiovascular risk and metabolic comorbidities, as these are the leading causes of death in this population. NICE also recommends non-invasive fibrosis assessment using the FIB-4 score as an initial step in primary care. A FIB-4 score below 1.30 generally indicates low risk of advanced fibrosis, while a score of 2.67 or above warrants further assessment, typically with an enhanced liver fibrosis (ELF) test or elastography, and referral to hepatology where indicated. People with suspected advanced fibrosis, cirrhosis or decompensated liver disease should be referred promptly to a specialist.

Patients and carers should be aware of symptoms that require urgent medical attention, including jaundice (yellowing of the skin or whites of the eyes), ascites (abdominal swelling due to fluid), confusion or drowsiness that may suggest hepatic encephalopathy, vomiting blood or passing black tarry stools, and severe abdominal pain with fever. Anyone experiencing these symptoms should seek urgent medical care.

NHS treatment for fatty liver disease currently centres on lifestyle modification. This includes a sustained reduction in body weight (typically 7 to 10 per cent of total body weight), a balanced diet low in ultra-processed foods and added sugars, and regular physical activity. For people with MASLD, alcohol advice should follow UK low-risk drinking guidelines (no more than 14 units per week, spread across three or more days, with several alcohol-free days), unless a clinician advises otherwise.^[5][6] For people with alcohol-related liver disease, complete abstinence from alcohol is essential. Management of associated conditions such as type 2 diabetes, hypertension and dyslipidaemia is also a core part of care. As of the time of writing, no medicine is specifically licensed in the UK for MASLD; this is a rapidly evolving area and patients should check with their GP or specialist for the most current position, as NICE guidance continues to be updated as new evidence emerges.

Is there any evidence that ivermectin helps with fatty liver?

There is no robust clinical evidence that ivermectin benefits fatty liver disease in humans, and it is not licensed or recommended for this purpose by the MHRA or any UK clinical guideline.

There is currently no robust clinical evidence that ivermectin is beneficial for fatty liver disease in humans, and it is not recommended or licensed for this purpose in the UK. Ivermectin is an antiparasitic medicine authorised by the MHRA for specific indications, including the treatment of certain parasitic infections such as strongyloidiasis and onchocerciasis, as set out in the relevant UK Summary of Product Characteristics (SmPC). Its established role is entirely within infectious and parasitic disease, not metabolic or liver conditions.

Interest in ivermectin for metabolic conditions arose partly from preclinical (laboratory and animal) research suggesting that the drug may influence certain molecular pathways involved in lipid metabolism and inflammation. Some animal studies, particularly in rodent models, have observed reductions in hepatic fat accumulation or markers of liver inflammation following ivermectin administration. These findings generated scientific curiosity, but animal models of fatty liver do not reliably predict outcomes in humans, and results from cell or rodent studies cannot be directly applied to clinical practice.

It is important to note that ivermectin gained widespread public attention during the COVID-19 pandemic, during which it was promoted by some groups as a treatment for a range of conditions beyond its licensed indications. The EMA issued a public statement advising that ivermectin should not be used for COVID-19 outside clinical trials, and the MHRA similarly advised against its use outside authorised indications.^[10][11] This context is relevant because some of the online claims about ivermectin and fatty liver originate from the same period of misinformation, rather than from peer-reviewed clinical research.

Patients should also be aware that veterinary ivermectin products, formulated for use in animals, must never be used by humans. These products are not manufactured or dosed for human use and could cause serious harm. Only human-licensed ivermectin preparations, prescribed by a qualified clinician for an authorised indication, should ever be used.

Adverse effects associated with ivermectin, as listed in the UK SmPC and patient information leaflet, include dizziness, nausea, diarrhoea, skin reactions and, at higher doses, neurological effects. Anyone who experiences a suspected adverse reaction to a medicine they are taking should report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Patients should be cautious about health claims that are not supported by evidence from well-designed human trials.

What does current UK and international research actually show?

Current research on ivermectin and fatty liver remains at an early preclinical stage, with no high-quality human randomised controlled trials, and neither NICE nor EASL guidelines reference it as a treatment option.

Current research on ivermectin and fatty liver disease remains at an early, exploratory stage, and no high-quality randomised controlled trials in humans have established a clinical benefit for MASLD or MASH. The available evidence consists primarily of in vitro (cell-based) studies and animal experiments, which, while sometimes promising in a mechanistic sense, do not constitute proof of efficacy or safety in people with these conditions.

Some preclinical studies have suggested that ivermectin may activate certain nuclear receptors, including the farnesoid X receptor (FXR) and pregnane X receptor (PXR), which play roles in bile acid metabolism and lipid regulation. Researchers have proposed that these mechanisms could theoretically reduce hepatic fat or inflammation. However, the doses used in many animal studies are not directly comparable to doses used in humans for antiparasitic treatment, and the pharmacokinetics differ substantially between species. These mechanistic observations remain unreplicated in human clinical trials.

No NICE technology appraisal or NICE clinical guideline, as of the time of writing, references ivermectin as a treatment option for fatty liver disease. Similarly, the European Association for the Study of the Liver (EASL) does not include ivermectin in its clinical practice guidelines for the management of MASLD or MASH. The absence of human trial data means that any potential benefit remains entirely theoretical, and the regulatory and guideline position may be verified by consulting the relevant NICE and EASL publications directly.

Using ivermectin outside its licensed indications carries real risks, as described in the previous section. Self-medicating with ivermectin for fatty liver is not supported by evidence and could cause harm.

What treatments are recommended for fatty liver in the UK?

NICE recommends sustained weight loss of at least 7 to 10 per cent, dietary improvement and increased physical activity as the most effective treatments for fatty liver, with pharmacological options for obesity considered where clinically appropriate.

The most effective and evidence-based treatments for fatty liver disease in the UK remain lifestyle interventions, particularly sustained weight loss, dietary improvement and increased physical activity. NICE guidance recommends that people with MASLD aim to lose at least 7 to 10 per cent of their body weight, as this level of weight reduction has been shown to reduce liver fat, improve liver enzyme levels and, in some cases, reverse early fibrosis. Even modest weight loss of 3 to 5 per cent can reduce hepatic steatosis.^[1][12] These targets are also supported by EASL clinical practice guidelines for MASLD and MASH.

For people with obesity and MASLD, weight management support through NHS services may include structured dietary programmes, behavioural support and, where clinically appropriate, pharmacological treatment for obesity. Orlistat is an established licensed option for weight management in the UK. Medicines such as semaglutide (Wegovy, licensed in the UK for chronic weight management, with a maintenance dose of 2.4 mg weekly and a higher-dose 7.2 mg weekly option also available in the UK) and tirzepatide (Mounjaro, authorised in the UK for both type 2 diabetes and chronic weight management) have demonstrated significant effects on body weight and are being studied for their impact on liver disease.^[13][14] NHS access to these medicines depends on national commissioning decisions and local Integrated Care Board (ICB) pathways, as set out in the relevant NICE Technology Appraisals. These medicines are prescribed only where clinically appropriate, following assessment by a qualified prescriber. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where medicines such as these may be one option a prescriber considers after a thorough clinical assessment.

Management of associated metabolic conditions is equally important. Optimising blood glucose control in type 2 diabetes, treating dyslipidaemia and managing blood pressure all contribute to reducing the risk of liver disease progression. The NICE-aligned pathway for MASLD includes non-invasive fibrosis assessment using FIB-4 in primary care, with onward testing using the ELF test (as described in NICE guidance DG34) or elastography where indicated, and referral to hepatology for those with suspected advanced fibrosis or cirrhosis. People with suspected advanced fibrosis or cirrhosis should be referred to a hepatologist for specialist assessment. If you are concerned about your liver health, speak to your GP in the first instance, who can arrange appropriate blood tests and imaging.

Frequently Asked Questions